Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Open Access
- 1 October 2017
- journal article
- review article
- Published by Informa UK Limited in Drug Design, Development and Therapy
- Vol. ume 11, 2905-2919
- https://doi.org/10.2147/dddt.s114932
Abstract
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date Francesca Cinti,* Simona Moffa,* Flavia Impronta,* Chiara MA Cefalo, Vinsin A Sun, Gian Pio Sorice, Teresa Mezza, Andrea Giaccari Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy *These authors contributed equally to this work Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients. Keywords: antidiabetic drugs, glycosylated hemoglobin, glycemic control, sodium-glucose cotransporter 2 inhibitors, precision medicine, type 1 diabetes mellitus, type 2 diabetes mellitus, weight reductionKeywords
This publication has 57 references indexed in Scilit:
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 DiabetesJournal of Investigative Medicine, 2017
- Sodium‐glucose co‐transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2017
- Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study GroupCardiovascular Diabetology, 2017
- Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneDiabetes, Obesity and Metabolism, 2017
- Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibitionDiabetes, Obesity and Metabolism, 2015
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2014
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 InhibitorsJournal of Medicinal Chemistry, 2011
- Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatmentNutrition, Metabolism and Cardiovascular Diseases, 2009